A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma — Stella

Recruiting

Back to Multiple Myeloma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital, Tianjin

Key details

Phase

Early testing / Safety & dosing

Sponsor

Shanghai AbelZeta Ltd.

Enrollment target

~92 participants

Started

November 2022

Primary completion

July 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated March 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov